Navigation Links
Live Case at TCT Mirrors PRS Patient Specific Simulation Rehearsal
Date:12/13/2012

CLEVELAND, December 13, 2012 /PRNewswire/ --

The Simbionix PROcedure™ Rehearsal Studio (PRS) was put to the test when Barry T. Katzen, MD, FACR, FACC, FSIR, Founder/ Medical Director of Baptist Cardiac and Vascular Institute utilized the technology to pre-operatively plan and rehearse for a Live Case he performed at the 2012 TCT Conference.  Following the rehearsal done in advance of the surgery, Dr. Katzen performed the EVAR endovascular intervention live at the TCT.  This "Future Techniques for Endovascular Therapy" session demonstrated new techniques for possible improvements on a variety of procedures in the endovascular space.  

     (Logo: http://photos.prnewswire.com/prnh/20120502/529202-a)

The practice session involved the pre-operative review of the patient's anatomy, selection of tools dedicated for EVAR procedure, including deploying a Gore C3 Excluder endoprosthesis .The patient had challenging anatomy with a lot of iliactortuosity and a fairly big flow lumen which posed technical challenges for the group of physicians doing this procedure.  

The patient's CT scan was downloaded into the PRS which allowed Dr. Katzen to create a patient-specific 3D virtual anatomical model.  Dr. Katzen used it to plan and practice the endovascular intervention which included the identification of the appropriate access strategy, selection of tools, guide wires, catheters, endoprosthesis as well as choosing the effective fluoroscopic views.

At TCT, Dr. Katzen showed the practice video and then performed the actual surgery on the patient they had rehearsed earlier. The live case replicated the rehearsal. http://simbionix.com/simbionix_videos/tct-2012-evar-live-case-video/

"The patient presented several anatomic challenges that were realistically demonstrated in the simulator," said Dr. Katzen.

"As a result of the PRS simulation, we reevaluated our measurements and modified the right side of the limb.  We verified, went back and recalculated everything and basically adjusted the right limb size. We felt that it was going to work and it did," said Dr. Katzen. "The simulation has predicted type Ib endoleak in the right limb which we actually corrected with a balloon and didn't have to put in another graft."

"I find the rehearsing part of the simulation incredibly interesting," said Dr. Katzen.  "This will be great for a surgeon or an Interventionalist because it is all about better outcomes."

About Simbionix:

Simbionix is the world's leading provider of medical simulation training and education products for medical professionals and the healthcare industry. Visit: http://www.simbionix.com   Facebook, Twitter and LinkedIn.  

Contact: Susan Vetrone, North American Director of Marketing susanv@simbionix.com, +1-216-2292040



'/>"/>
SOURCE Simbionix Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. CureLauncher is a New Website That Connects Patients to Trials Across the U.S.
2. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
3. Moscow State University Hospital Selects Ekahau RTLS to Improve Operations and Patient Safety
4. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
5. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
6. New Ray of Hope for HIV Patients
7. DioGenix MSPrecise Identifies Early-Stage Patients with Multiple Sclerosis
8. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
9. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
10. Patient Safety Technologies Reports Third Quarter 2012 Results
11. Multimodal Treatment of Peritoneal Metastases Offers Hope for Many Patients With Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... The effectiveness of ... assessed in clinical trials in the United States. (clinicaltrials.gov : NCT02973893) , To ... physician or find your nearest participating clinic here https://factor-therapeutics.com/clinical-trials/ and discuss ...
(Date:9/21/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... from DrugDev , a QuintilesIMS company, who enable the world’s most progressive ... learned from over 2,000 clinical trials at top pharma and biotech events in ...
(Date:9/20/2017)... ... 2017 , ... The award-winning producers behind the American Farmer ... innovations aimed at helping farmers solve the problem of nitrogen loss. The upcoming ... 8:30aET on RFD-TV. Check your local listings for more info. , As ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... of a study examining the effects of exoskeleton-assisted walking on gait parameters ... (SCI). The article, "Neuromechanical adaptations during a robotic powered exoskeleton assisted walking ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):